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Background. Inﬂuence of TMPRSS6 A736V and HFE (C282Y and H63D) polymorphisms on serum hepcidin-25 levels and iron
status parameters in end-stage renal disease (ESRD) patients stratiﬁed according to gender has not been previously investigated.
In addition, we aimed to evaluate the diagnostic accuracy of the parameters to separate iron-deﬁciency anemia (IDA) from
anemia of chronic disease. Materials and Methods. Iron status parameters and genetic analysis were performed in 126 ESRD
patients and in 31 IDA patients as the control group. Results. ESRD patients had signiﬁcantly higher ferritin and hepcidin-25
(<0.001) relative to IDA patients. Cut-oﬀ values with the best diagnostic accuracy were found for hepcidin ≥9.32 ng/mL, ferritin
≥48.2μg/L, transferrin saturation ≥16.8%, and MCV ≥81 fL. Interaction between gender and HFE haplotypes for the
hepcidin-25 and ferritin levels in ESRD patients (p = 0 005, partial eta squared = 0 09; p = 0 027, partial eta squared = 0 06,
respectively) was found. Serum transferrin was inﬂuenced by the combined eﬀect of gender and TMPRSS6 A736V
polymorphism in ESRD patients (p = 0 002, partial eta squared = 0 07). Conclusion. Our ﬁndings could contribute to the further
investigation of mechanisms involved in the pathophysiology and important gender-related involvement of the TMPRSS6 and
HFE polymorphisms on anemia in ESRD patients.
1. Introduction
Anemia of chronic disease (ACD), called “anemia of
inﬂammation”, is associated with infection, inﬂammation,
malignancy, and in many conditions. It is well-known that
inﬂammation in ACD could be associated with functional
iron deﬁciency, characterized by normal or elevated body
iron, locked in iron stores, and unavailable for erythropoie-
sis [1]. The classic sideropenic anemia is severe anemia
with microcytic, hypochromic erythrocytes, with low serum
iron, decreased transferrin saturation, and very low ferritin
level. Also, the best way to diagnose anemia of chronic dis-
ease is to prove a mild or moderate decrease of hemoglobin
with normocytic normochromic erythrocytes, low serum
iron, and TIBC with normal transferrin saturation, as well
as normal or elevated ferritin. To conﬁrm the presence of
coexisting iron deﬁciency (ID) in ACD, it is necessary to
use more speciﬁc tests like sTfR and sTfR/index [2].
A molecular mechanism that explains the redistribu-
tion of iron during inﬂammation is connected with
cytokine-stimulated overproduction of hepcidin. Recent
studies have conﬁrmed that hepcidin-25, a bioactive form
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of hepcidin, plays a central role in the regulation of iron
metabolism and reduces the amount of iron in circulation
[3–5]. Hepcidin synthesis is regulated at the transcriptional
level by multiple stimuli [3]. Intracellular and extracellular
iron concentrations increase hepcidin transcription, as does
inﬂammation, whereas increased erythropoietic activity
suppresses hepcidin production [4]. In turn, hepcidin reg-
ulates plasma iron concentrations by controlling ferropor-
tin concentrations on iron-exporting cells including
duodenal enterocytes, recycling spleen and liver macro-
phages, and hepatocytes [5–7].
Hepcidin deﬁciency is a result of autosomal recessive
mutations in the hepcidin gene or genes encoding hepcidin
regulators, the hemochromatosis gene (HFE, most com-
monly mutated in hereditary hemochromatosis in Cauca-
sians populations), transferrin receptor 2 (TfR2), or
hemojuvelin [8]. Consequently, the iron exporter ferroportin
is overexpressed on the basolateral membranes of duodenal
enterocytes which results in the development of systemic
iron overload due to excessive iron absorption. The most
frequent polymorphism of the HFE gene, located in the
short arm of chromosome 6 (6p), is at position 845, where
guanine (G) is replaced by adenine (A), resulting in the
replacement of a cysteine by tyrosine at position 282 of the
HFE protein sequence (C282Y), which leads to a nonfunc-
tional protein [9]. The C282Y polymorphism prevents
HFE protein from reaching the cell surface, thus preventing
the interaction with hepcidin and TFRs [9]. The second
most frequent HFE gene polymorphism consists of histidine
to aspartic acid replacement at position 63 of the HFE pro-
tein sequence (H63D), due to a cytosine (C) to guanine
(G) replacement at position 187. This polymorphism may
disrupt iron homeostasis and cause iron accumulation when
it cooccurs with the C282Y polymorphism [10].
The TMPRSS6 gene, mapping to chromosome
22q12-q13, encodes for matriptase-2, a membrane-bound
protease that decreases hepcidin transcription by cleaving
hemojuvelin [11]. According to dbSNP genetic variations
archive (NCBI), rs855791 identiﬁes thymine (T)>C substi-
tution in position 2207 (correspondent to a complemen-
tary A>G change), resulting the missense valine (V) to
alanine (A) change in position 736 (p.V736A variant),
nearby catalytic and binding sites of matriptase-2 [12].
Loss-of-function germline mutations of TMPRSS6 cause
iron-refractory iron-deﬁciency anemia. This is a rare type
of anemia characterized by a lack of response to oral iron
therapy but with partial response to parenteral iron adminis-
tration [13]. Consequently, the change of the suppressive
eﬀect of TMPRSS6 protein on hepcidin production is charac-
terized by extremely high hepcidin levels, whereas common
rs855791 polymorphisms resulting in the p.A736V substitu-
tion is a signiﬁcant determinant of iron status in healthy
subjects and decrease hemoglobin concentration [12, 14].
Patients undergoing end-stage renal disease (ESRD) are
commonly aﬀected by anemia, which is related to erythro-
poietin (EPO) deﬁciency, blood losses, and chronic inﬂam-
mation, which is the main diﬀerence compared to IDA
[12]. Literature data suggest that renal anemia is normocy-
tic and normochromic, often with coexisting iron deﬁciency
[14]. ESRD patients are characterized by major alterations
in iron metabolism including reduced iron availability for
the erythroblasts and hyperferritinemia [15]. Upregulation
of the serum levels of hepcidin has been proposed to
explain the alterations of iron metabolism of ESRD patients
and the resistance to anemia treatment [16, 17]. Epidemio-
logical studies in the population of Serbia have shown that
the prevalence of ESRD in adults is 0.07%, with commonly
presented anemia of chronic disease [18].
This study aimed at evaluating serum hepcidin-25 con-
centration and iron status parameters in a population-based
cohort of ESRD and IDA patients, as well as whether the
polymorphism TMPRSS6 A736V and HFE (C282Y and
H63D) aﬀect serum hepcidin-25 levels and iron status
parameters in the analyzed patients.
2. Materials and Methods
2.1. Study Population. This cross-sectional study was con-
ducted on 126 ESRD patients treated at the Clinical Center
of Serbia, Clinic of Nephrology, between February 2016 and
May 2017. According to the KDIGO guideline and glomer-
ular ﬁltration rate (GFR), all the analyzed patients were cat-
egorized as G5 stage of chronic kidney disease [19].
Patients were dialyzed with synthetic biocompatible mem-
branes and bicarbonate dialysate three times per week.
Patients were administered with i.v. synthetic erythropoie-
tin (EPOetin alfa-Eprex), at a dose, aimed to maintain
hemoglobin between 105 and 120 g/L. Iron was adminis-
tered i.v. as Fe3+-hydroxide saccharose complex. Patients
with IDA (n = 31) have been selected as control group, with
hemoglobin concentration < 110 g/L, MCV < 80 fL, FRT <
20μg/L, and CRP < 10 mg/L [20]. The exclusion criteria
for studied patients were known or suspected liver disease,
immunosuppressive therapy, thalassemic trait, and patients
with other known causes of anemia (e.g., inﬂammation and
neoplasia). Moreover, we excluded from the study all
patients aged <18 years, pregnant women, or patients with
discordant antibodies. According to the report of the World
Health Organization, the prevalence rate of sideropenic
anemia is speciﬁcally higher among women in reproductive
age which is why the IDA group was made up only of
female patients [21]. Most frequently associated diseases
with TMPRSS6 and HFE studied alleles in ESRD population
were hypertension and diabetes. Glomerulonephritis, poly-
cystic disease, pyelonephritis, and other diseases (calculosis,
sarcoidosis, gastritis, parathyroid disease, osteoporosis, and
pulmonary and cardiac disease) were also present in lower
degree. All patients gave informed consent to participate
in the study, which was conducted according to the Hel-
sinki Declaration and approved by the Ethics Committee
of the Clinical Center of Serbia.
2.2. Biochemical Parameters. Venous blood samples for com-
plete blood count, iron parameters, CRP, and genetic analysis
were drawn via antecubital venipuncture and collected in the
morning before hemodialysis, after one week after the last dose
of i.v. iron, and three days after the last dose of EPO. Aliquots
of the serum samples were stored at −80°C until the analysis.
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Complete blood count was measured by ﬂow cytometry
on Coulter LH750 haematology analyzer (Beckman Coulter
Diagnostics, USA). Urea, creatinine, iron, and unsaturated
iron-binding capacity (UIBC) were determined by spectro-
photometry and FRT, TRF, and CRP by a turbidimetric
method on Olympus AU2700 analyzer (Beckman Coulter
Diagnostics, Germany). We used the Modiﬁcation of Diet
in Renal Disease (MDRD) equation to estimate GFR [22].
Iron and UIBC values were used for TIBC calculation
[23]. TSAT was calculated with the formula used iron and
TIBC concentrations. Serum hepcidin-25 concentrations
were determined using chemiluminescent direct ELISA
technique (Corgenix, Inc., USA). We used each manufac-
turer’s commercial control samples to check method speci-
ﬁcations. Intra-assay CVs for all measured biochemical
parameters were <5%.
2.3. Genetic Analysis.DNAwas extracted from the blood sam-
ples with Na-citrate as anticoagulant, using commercial
QiAamp DNA Blood Mini kit (Qiagen Inc., Germantown,
Maryland, USA). For genotypization of HFE genotype
(C282Y andH63D variants) and the TMPRSS6 rs855791 poly-
morphism, (p.A736V variant), TaqMan predesigned SNP
assays (Thermo Fisher Scientiﬁc Inc., Waltham, MA, USA)
were performed on Applied Biosystems 7500 Real-Time
PCR instrument, and acquired data were analyzed.
2.4. Statistical Analysis. Normality of continuous variables
was assessed by the one-sample Kolmogorov–Smirnov test
(K-S test). According to the normality of distribution, we
applied the appropriate tests. Independent sample T-test,
Mann–Whitney U test, one-way ANOVA, and univariate
analysis of variance (two-way ANOVA) with the appropri-
ate post hoc analysis (least signiﬁcant diﬀerence test and
Sidak’s multiple comparison test) were used for the compar-
ison of continuous variables among the groups. Chi-square
test was used for the analysis of categorical variables. Devia-
tions of genotypes’ distributions from Hardy–Weinberg
equilibrium were assessed by χ2-test for each cohort or Fish-
er’s exact test (if cases were <5). Receiver operating charac-
teristic (ROC) curve analysis was used for the evaluation of
iron status parameters diagnostic characteristics and for
the determination of the optimal cut-oﬀ values which diﬀer-
entiate between iron-deﬁciency anemia and anemia of
chronic disease. Statistical analysis was performed using
IBM SPSS Statistics version 20.0 (Chicago, IL). A post hoc
statistical power analysis was conducted using the
QUANTO software, version 1.2 for SNPs, TMPRSS6
A736V variants, and HFE gene variants (C282Y and H63D
variants) [24]. The haplotype analysis of two SNPs of HFE
genes (H63D and C282Y) was done with haplotype analysis
software [25]. In this study, a value of p < 0 05 was consid-
ered statistically signiﬁcant.
3. Results
Two diﬀerent pathogenic types of anemia have been exam-
ined from the aspects of iron status parameters and the SNPs
of three genes (TMPRSS6 A736V, HFE C282Y, and HFE
H63D). The iron-deﬁciency anemia (IDA) was investigated
in a group of 31 sideropenic patients and a group of patients
with ACD that included 126 ESRD subjects.
Clinical characteristics of these two patient groups were
presented in Table 1. The obtained very high levels of serum
creatinine and urea, as well as very low estimated glomerular
ﬁltration rates (eGFR), are the expected characteristics of the
dialyzed patients. The ESRD group of patients showed sig-
niﬁcantly higher levels of CRP compared to patients with
sideropenic anemia (about two times), which is an indicator
of chronic inﬂammation in ESRD patients. Both patient
groups had clinically manifested anemia, with approxi-
mately the same hemoglobin levels. Diﬀerences in an iron
status proﬁle obtained in two patient groups corresponded
with the pathophysiology diﬀerence of the speciﬁc anemia.
Thus, in the ESRD group of patients with ACD, we found sig-
niﬁcantly increased serum iron, transferrin saturation, and
MCV, as well as decreased TIBC, transferrin levels, and solu-
ble transferrin receptor levels. Signiﬁcantly increased levels of
ferritin (about 32 times) and hepcidin-25 (about 18 times)
were obtained in ESRD patients in comparison to patients
with sideropenic anemia.
There was no diﬀerence in the frequency distribution of
TMPRSS6 A736V, HFE C282Y HFE H63D gene variants,
and HFE haplotypes between two groups of patients
(Table 2). Frequencies of TMPRSS6 A736V genotypes and
alleles in both patient groups were consistent with Hardy–
Weinberg equilibrium. In both investigated patient groups,
there were missing rare homozygote variants for the HFE
H63D G/G and for the HFE C282Y A/A.
Assuming the prevalence of ESRD in Serbian adults of
0.07% (commonly with anemia of chronic disease), a post
hoc power analysis showed that the recruited 126 patients
with ESRD and 31 patients with sideropenic anemia
(iron-deﬁcient anemia) have power for identifying the
associations (log-additive model of inheritance) 66% for
TMPRSS6 A736V, 27% for HFE H63D, and 17% for
HFE C282Y gene variants.
Receiver operating characteristic (ROC) curve analysis
of diagnostic value of iron-status biomarkers in distinguish-
ing between IDA (sideropenic anemia) and ACD (ESRD
patients) was shown excellent diagnostic properties for hep-
cidin-25, ferritin, transferrin saturation, and MCV, with
area under the curve AOC > 0 9 (Figure 1). Precisely,
for hepcidin-25, AOC was 0.932 (St.error 0.021, p < 0 001);
for ferritin, AOC was 0.991 (St.error 0.006, p < 0 001);
for transferrin saturation, AOC was 0.958 (St.error 0.017,
p < 0 001); and for MCV, AOC was 0.988 (St.error 0.007;
p < 0 001). The cut-oﬀ values with the best diagnostic accu-
racy were obtained for hepcidin ≥9.32 ng/mL (speciﬁcity
100%, sensitivity 90%), for ferritin ≥48.2μg/L (speciﬁcity
100%, sensitivity 87%), for transferrin saturation ≥16.8%
(speciﬁcity 84%, sensitivity 91%), and for MCV ≥81 fL (spec-
iﬁcity 100%, sensitivity 90%).
ESRD patients with clinically manifested anemia showed
gender-related diﬀerences in iron status, inﬂammation, and
severity of renal disease (Table 3). In ESRD patients, males
had higher serum iron levels, RBC and lower MCV, higher
CRP levels, and higher eGFR.
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There were no diﬀerences in the frequency distribution of
gene variants of TMPRSS6 A736V, HFE H63D, HFE C282Y,
and HFE haplotypes between genders in the ESRD group of
patients (Table 4).
The main results of this study were combined inﬂuence
of gender and haplotypes of two HFE genes, as well as
TMPRSS6 A736V variants on the biomarkers of iron status.
We found the statistically signiﬁcant interaction between
gender and haplotypes of two HFE genes (H63D/C282Y) on
the serum levels of hepcidin-25 and ferritin in ESRD patients
(p = 0 005, partial eta squared = 0 09; p = 0 027, partial eta
squared = 0 06, respectively) (Figure 2). Using post hoc
Sidak’s multiple comparison test, we found that males with
haplotype C282Y/wt has signiﬁcantly increased levels of
hepcidin-25 compared to males with haplotype H63D/wt
(p = 0 002), males with haplotype wt/wt (p = 0 002), and
females with the same haplotype C282Y/wt (p = 0 001)
(Figure 2(a)). Additionally, gender-related diﬀerences in the
serum ferritin levels showed that males with a haplotype
C282Y/wt had higher ferritin level than females with the
same haplotype (p = 0 029) (Figure 2(b)).
The levels of serum transferrin were inﬂuenced by the
combined eﬀect of gender and TMPRSS6 A736V gene vari-
ants in ESRD patients (p = 0 002, partial eta squared = 0 07)
(Figure 3(a)). According to the TMPRSS6 A736V gene vari-
ants, we analyzed a group of G/G homozygotes versus car-
riers of A allele (homozygotes A/A or heterozygotes A/G)
according to the dominant model of inheritance. Females
who carry a risk A allele have lower level of transferrin than
G/G homozygote females (p = 0 002) and males regardless
of the TMPRSS6 gene variants (vs. G/G males, p = 0 018; vs.
Table 1: Characteristics in two patient groups with IDA (sideropenic anemia) and ACD (ESRD patients).
Characteristic Sideropenic anemia (n = 31) ESRD patients (n = 126) p
Gender (females) (%) 100 44 <0.001
Age (years) 42 (33-47) 61 (46-66) <0.001
Serum urea (mmol/L) 4.00 (3.40-4.90) 19.90 (17.02-23.22) <0.001
Serum creatinine (μmol/L) 65.00 (58.00-70.00) 766.00 (592.25-913.25) <0.001
eGFR (mL/min/1.73m2) >60 6.00 (5.00-7.00) —
Hepcidin-25 (ng/mL) 3.00 (2.74-3.05) 53.98 (18.82-110.51) <0.001
Hemoglobin (g/L) 103.00 (97.30-111.70) 104.95 (95.82-113.78) 0.776
Serum iron (μmol/L) 6.00 (3.90-9.90) 11.9 (9.85-15.55) <0.001
TIBC (μmol/L) 69.50 (62.60-73.30) 40.60 (35.18-47.52) <0.001
Transferrin (g/L) 3.18 (2.87-3.30) 1.73 (1.56-1.91) <0.001
TS (%) 8.40 (5.30-14.60) 29.80 (23.40-37.25) <0.001
sTfR (mg/L) 2.43 (1.94-3.51) 1.25 (0.93-1.64) <0.001
Ferritin (μg/L) 8.00 (8.00-8.50) 256.70 (81.35-593.15) <0.001
CRP (mg/L) 1.20 (0.50-3.00) 2.70 (1.50-7.90) <0.001
RBC (×1012/L) 4.23 (4.09-4.54) 3.41 (3.15-3.74) <0.001
WBC (×109/L) 6.75 (5.66-8.45) 6.44 (5.55-7.80) 0.586
MCV (fL) 75.88 (71.01-78.00) 93.88 (91.00-97.16) <0.001
RDW (fL) 17.05 (15.70-18.06) 15.02 (13.99-16.35) <0.001
Continuous variables were presented as median (interquartile range); ESRD: end-stage renal disease; eGFR: estimated glomerular ﬁltration rate; TIBC: total
iron-binding capacity; TS: transferrin saturation; sTfR: soluble transferrin receptor; CRP: C-reactive protein; RBC: red blood cell count; WBC: white blood
cell count; MCV: mean corpuscular volume; RDW: red cell distribution width.
Table 2: Frequency distribution of TMPRSS6 A736V, HFE C282Y,
andHFEH63D gene variants (expressed as %) in two patient groups
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males with risk A allele, p = 0 048). The combined inﬂuence
of gender and TMPRSS6 A736V gene variants on transferrin
saturation was shown in Figure 3(b). Although the inﬂuence
was not signiﬁcant and probability was very close to signiﬁ-
cance (p = 0 058, partial eta squared = 0 03), we found that
transferrin saturation in females with risk A allele was higher
than in females who were homozygotes G/G, but probability
was close to signiﬁcant (p = 0 063).
4. Discussion
Many literature data are dealing with the fact that
hepcidin-25 is a signiﬁcant iron status regulator and may
serve as an important mediator in the pathogenesis of the
anemia of chronic disease. In relation to this issue, there is
a number of studies conducted in a population of patients
with ESRD [14–17, 26, 27]. Direct measurement of the bio-
active isoform of the hormone, hepcidin-25 in serum, is a
reliable marker of iron homeostasis in this particular patient
population because only in this form hepcidin is
independent of glomerular ﬁltration rate [28]. However,
there is no ﬁnal agreement whether hyperhepcidinemia is a
constant and distinct feature of ESRD patients. Moreover,
there is no consensus about the diagnostic characteristics
for hepcidin-25 to distinguish IDA from ACD [17]. Proba-
bly the reason for this is that control groups in previous
studies were not adequately selected. The inclusion of
healthy participants in a control group on the basis of acute
phase protein concentrations (CRP, FRT) and serum iron
concentration is unreliable to exclude subclinical character-
istics of anemia [17]. Regarding this, we have selected IDA
patients with normal GFR and without inﬂammation (CRP
<10mg/L) as a control group, whereas ESRD patients were
chosen on the basis of the present ACD.
We found excellent diagnostic properties for hepci-
din-25, FRT, TSAT, and MCV for distinguishing IDA from
ACD in ESRD patients. We presented the best diagnostic
characteristic at 9.32 ng/mL for hepcidin-25 which is consis-
tent with literature data [17, 26, 29]. Valenti et al. have stated
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Figure 1: Receiver operating characteristic (ROC) curve analysis of diagnostic value iron-status biomarkers in distinguishing between IDA
(sideropenic anemia) and ACD (ESRD patients): (a) hepcidin-25; (b) ferritin; (c) transferrin saturation; (d) MCV.
5Disease Markers
patients included in the second and third hepcidin quartiles
(1.56–49.8 ng/mL) [17]. The concentration of hepcidin-25
which was obtained as the cut-oﬀ value in our study is in
the lower quartile of the presented range and agrees with
the result of Wagner et al. [27]. Additionally, FRT concentra-
tions are mostly within recommended ranges for these
patients and indicate the absence of inﬂammation. However,
there is an extensive range for FRT cut-oﬀ values in iron deﬁ-
ciency, and it is diﬃcult to exclude coexisting iron depletion,
particularly in the presence of inﬂammation or underlying
disease. In this study, we have obtained very high speciﬁcity
and sensitivity at 48.2μg/L FRT concentrations, which is
the expected value and in agreement with previously
reported data [26, 30, 31]. We have obtained the best speciﬁc-
ity and sensitivity for the cut-oﬀ value of 16.8% for TSAT.
This value tells us that there is enough iron to meet the basic
needs of erythropoietic tissue in our patients. Although rec-
ommended TSAT value of ≥20% principally refers to a
healthy population, our lower result is expected because stud-
ied patients had a chronic renal impairment. Based on the
RBC indices, anemia with MCV <80 fL was classiﬁed as
microcytic and is characteristic for IDA, contrary to normo-
chromic normocytic anemia which is a standard feature in
ACD patients [32]. The obtained cut-oﬀ value for MCV, at
81 fL, with very high diagnostic properties in studied
patients, agrees with literature data and presents an equally
important parameter for distinguishing two types of ane-
mia particularly in ESRD patients. Despite very high sensi-
tivity and speciﬁcity, these parameters only jointly
examined can predict iron status and could help in the
administration of iron and erythropoiesis-stimulating
agents in ESRD patients.
We found gender-related diﬀerences in iron status and
inﬂammation in ESRD patients with clinically manifested
anemia. Males with ESRD had an expected higher RBC and
hemoglobin concentrations. Additionally, it is generally
accepted that females had a higher prevalence of anemia than
males, but that anemia in chronic kidney disease positively
correlates with age in both genders [33]. This is because the
population of ESRD patients included older persons, and
the genetic eﬀects on iron status from menstrual blood loss
were minimized [34]. A possible reason that we did not ﬁnd
a diﬀerence in FRT concentrations in regard to gender is that
female patients in our study were no longer in the reproduc-
tive period and had reduced blood loss. Tomschi et al.
recently published that RBC indices were gender-related in
elite athletes, i.e., persons with activated erythropoiesis [35].
Higher concentrations for MCV in the study of ESRD
females could be a consequence of stimulated erythropoiesis
as a response to therapy in our patients. In our study, we
found lower CRP concentrations in female patients, which
is in line with the literature data that point out the
anti-inﬂammatory eﬀect of estrogen [36, 37].
Recent genome-wide association studies show that very
common single nucleotide polymorphisms in the TMPRSS6
gene represent, together with HFE mutations, a signiﬁcant
determinant of the variation in iron status in the general pop-
ulation [38]. TMPRSS6 A736V is common in the general
population, with previous studies indicating a prevalence of
45% for the risk-associated T-allele [39]. However, it is con-
ﬁrmed that associations of common variants in HFE
(C282Y and H63D) and TMPRSS6 (A736V) genes with iron
parameters are independent of serum hepcidin in a general
population [40]. There are few literature data about
Table 3: Gender-related characteristics in patients with ACD (ESRD).
Characteristic Females (n = 54) Males (n = 72) p
Age (years) 58.50 (43.25-66.00) 62.00 (47.25-67.75) 0.165
Serum urea (mmol/L) 19.85 (16.27-23.80) 19.95 (17.90-23.08) 0.530
Serum creatinine (μmol/L) 715.50 (518.50-852.7) 801.50 (661.50-979.25) 0.006
eGFR (mL/min/1.73m2) 5.00 (4.00-7.00) 6.00 (5.00-7.75) 0.060
Hepcidin-25 (ng/mL) 61.13 (22.94-110.62) 47.37 (13.93-110.91) 0.358
Hemoglobin (g/L) 101.75 (93.25-108.90) 107.25 (98.02-117.57) 0.012
Serum iron (μmol/L) 12.95 (10.30-15.70) 11.20 (9.02-15.35) 0.091
TIBC (μmol/L) 38.80 (34.40-46.45) 42.40 (36.65-48.17) 0.132
Transferrin (g/L) 1.65 (1.50-1.95) 1.77 (1.57-1.91) 0.379
TS (%) 29.00 (21.45-38.35) 30.10 (24.47-37.25) 0.641
sTfR (mg/L) 1.28 (1.08-1.73) 1.18 (0.82-1.56) 0.106
Ferritin (μg/L) 304.20 (99.95-616.95) 214.90 (77.75-548.73) 0.455
CRP (mg/L) 2.00 (1.35-4.67) 4.20 (2.00-10.15) 0.006
RBC (×1012/L) 3.38 (3.02-3.58) 3.49 (3.24-3.94) 0.018
WBC (×109/L) 6.31 (5.40-7.21) 6.75 (5.62-8.20) 0.141
MCV (fL) 94.94 (92.51-97.83) 93.12 (90.01-96.28) 0.027
RDW (fL) 14.72 (13.84-16.54) 15.27 (14.04-16.26) 0.317
Continuous variables were presented as median (interquartile range); ESRD: end-stage renal disease; eGFR: estimated glomerular ﬁltration rate; TIBC: total
iron-binding capacity; TS: transferrin saturation; sTfR: soluble transferrin receptor; CRP: C-reactive protein; RBC: red blood cell count; WBC: white blood
cell count; MCV: mean corpuscular volume; RDW: red cell distribution width.
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frequency distribution and particular eﬀect of these variants
in ESRD patients. We found no diﬀerence in the frequency
distribution of TMPRSS6 A736V, HFE C282Y, and HFE
H63D gene variants between IDA and ACD patients, which
are in agreement with Pelusi et al. [15]. Patients that have
been examined in this study lacked a rare homozygous vari-
ant HFE C282Y A/A and HFE H63D G/G. Several previous
studies have reported that the prevalence of the homozygos-
ity for HFE C282Y and HFE H63D mutations is very low in
Southern and Eastern Europe [29, 41–43]. It is well-known
that these variants are a common cause of hereditary hemo-
chromatosis, and patients included in this study did not have
this disorder. There are a number of studies trying to explain
the connection of diﬀerent common nonhematologic disor-
ders with the frequencies of TMPRSS6 andHFE gene variants
[8, 16, 43–45]. Knowledge of genetic iron disorders can help
to uncover other pathogenic or protective mechanisms in
major human diseases.
To our knowledge, this is the ﬁrst study that examines
diagnostic characteristics for hepcidin-25 and iron status
parameters in relation to TMPRSS6 A736V, HFE C282Y,
and HFE H63D polymorphism in ESRD patients. In this
study, no diﬀerences were found in the frequency
distribution of gene variants of TMPRSS6 A736V, HFE
H63D, HFE C282Y, and haplotypes of two HFE genes
(H63D and C282Y) between genders. Some studies indicate
that there is a gender-related diﬀerence in the distribution
of TMPRSS6 and HFE polymorphisms in some diseases
[29, 44], but no studies have so far analyzed ESRD patients
in this context. Moreover, we found higher serum levels of
hepcidin-25 and FRT in males than in females in relation
toHFE haplotypes. Literature data indicate that serum hepci-
din concentrations in males are constant over the age and
that they are higher compared to the concentrations in
females, who have a tendency of higher hepcidin concen-
trations as they progress through menopause [6].
However, our results for the ﬁrst time indicate a
gender-related diﬀerence in hepcidin-25 levels in relation
to the haplotypes of two HFE genes. Thus, male patients
with haplotype C282Y/wt had the highest serum levels of
hepcidin and ferritin. It seems that the presence of haplo-
type C282Y/wt in males lead to an increased hepcidin pro-
duction, which in turn inhibits iron release from
macrophages, with the consequently onset of anemia. Sim-
ilarly, in a very large Danish Blood Donor Study, Sørensen
et al. found that man heterozygous for either of the two
HFE variants had higher ferritin levels than in wt type
homozygous (the eﬀect was higher for HFE C282Y), while
no such diﬀerence was seen in women [46]. This observa-
tion could be clinically signiﬁcant in the treatment of ane-
mia in ESRD patients.
In addition, we found a signiﬁcantly decreased level of
serum transferrin with consequently increased transferrin
saturation in ESRD females who are carriers of A allele
(A/G and A/A) than females with wild-type homozygotes
G/G in TMPRSS6 gene. According to our best knowledge,
our results for the ﬁrst time showed that TMPRSS6 736Val
variant is associated with low levels of transferrin and high
transferrin saturation in ESRD females with anemia. Nai
et al. [39] observed that homozygosity for TMPRSS6
736Val (genotype A/A according to SNP nomenclature) is
associated with signiﬁcant higher levels of hepcidin-25, lower
transferrin saturation, and lower serum iron than in
TMPRSS6 736Ala homozygotes (genotype G/G according
to SNP nomenclature) in healthy individuals. These authors
also showed that the G allele of TMPRSS6 rs855791 inhibits
hepcidin more eﬃciently than the A allele. However, Gale-
sloot et al. showed that the inﬂuence of TMPRSS6 rs855791
variants to ferritin, serum iron, transferrin saturation, and
TIBC was not dependent on serum hepcidin in general pop-
ulation, adjusted for age and gender [47]. They found that
transferrin saturation was decreased and TIBC was increased
in individuals with TMPRSS6 A/G and A/A variants in com-
parison to TMPRSS6G/G homozygotes, which corresponded
with the ﬁndings in our study that were obtained in females
with ESRD. Gender-related diﬀerence in transferrin levels
and transferrin saturation associated with TMPRSS6
rs855791 variants in patients with ESRD-related anemia is
potentially clinical relevant, but the pathophysiological
mechanism should be examined in extensive studies.
A limitation of this study is a relatively small sample
size, which inﬂuenced the power for identifying the
Table 4: Gender-related frequency distribution of TMPRSS6
A736V, HFE C282Y, and HFE H63D gene variants (%) in patients
with ACD (ESRD patients).





A allele 39.0 44.0 0.377
H-W (χ2, p) 0.009 (0.923) 0.138 (0.710)
TMPRSS6 A736V (dominant model of inheritance)
G/G 37.0 31.9
0.551






G allele 13.9 8.3 0.158






A allele 2.8 2.1 0.720






associations of investigated gene variants between patients
with iron deﬁciency and anemia of chronic disease. So it is
necessary to continue further research with a larger num-
ber of samples.
In conclusion, in the assessment of anemia in ESRD, it
is essential to perceive not only traditional iron status
parameters but also hepcidin-25, as a critical regulator of
iron status. It remains to be clariﬁed whether the mecha-
nism by which hepcidin regulates iron metabolism is
aﬀected by the primary disorder in patients with ESRD.
Our ﬁndings could contribute to the further investigation
of mechanisms involved in the pathophysiology of anemia
in ESRD patients. Additionally, our results highlight the
important gender-related involvement of the TMPRSS6
and HFE polymorphisms on anemia in ESRD patients
and could help further research to investigate whether pri-
mary disorder itself modiﬁes patient’s response to anemia.
Data Availability
The authors declare that the data supporting the ﬁndings of
this study are available within the article or are available from





















































Haplotypes of HFE H63D and HFE C282Y
(b)
Figure 2: Gender-related eﬀect of haplotypes of twoHFE genes (HFEH63D andHFE C282Y) on the serum levels of (a) hepcidin-25 (ng/mL)




























































Figure 3: Gender-related combined eﬀect of polymorphism of TMPRSS6 A736V on the levels of (a) transferrin (g/L) and (b) transferrin
saturation (%) in patients with ACD (ESRD).
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